Placebo-Controlled, Parallel-Group Study of KRP-KC121E in Patients with Meibomian Gland Dysfunction

KRP-KC121E Phase 2 -A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study in Patients with Meibomian Gland Dysfunction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220407

Enrollment

Registered

2022-10-24

Start date

2022-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian Gland Dysfunction

Interventions

Eye instillation of KRP-KC121E or placebo to patients with Meibomian Gland Dysfunction

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Aged over 18 years at the time of Informed Consent(any gender) -Live in Japan -Have Meibomian Gland Dysfunction in both eyes -Meet the other protocol-specified inclusion criteria

Exclusion criteria

Exclusion criteria: -Unable to discontinue wearring contact lens during the study -Have history of, or scheduled ocular surgery during the study -Have active ocular disease -Have severe systemic illness -Known history of hypersensitivity to any of the drugs used in the study -Patient who is pregnant, lactating, potentially pregnant -Have judged that it is inappropriate to participate in this study by investigator -Meet the other protocol-specified exclusion criteria

Design outcomes

Primary

Measure	Time frame
Improvement in inflammation, adverse events etc.	—

Secondary

Measure	Time frame
Improvement in inflammation	—

Contacts

Public Contactdivision Clinical

Senju Pharmaceutical Co., Ltd.

senju-clinicaltrials@senju.co.jp+81-78-777-1018

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026